Patient-reported complications after cryoablation therapy for prostate cancer

By Badalament R.A.   Bahn D.K.   Kim H.   Kumar A.   Bahn J.M.   Lee F.  

Urology, Vol. 54, Iss. 2, 1999-08 ,pp. : 295-300

Elsevier

Access to resources Recommend Favorite

Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer

By Fowler J.E.   Flanagan M.   Gleason D.M.   Klimberg I.W.   Gottesman J.E.   Sharifi R.  

Urology, Vol. 55, Iss. 5, 2000-05 ,pp. : 639-642

Elsevier

Access to resources Recommend Favorite

An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer

By Sartor O.   Dineen M.K.   Perez-Marreno R.   Chu F.M.   Carron G.J.   Tyler R.C.  

Urology, Vol. 62, Iss. 2, 2003-08 ,pp. : 319-323

Elsevier

Access to resources Recommend Favorite

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

By Higano C.S.   Ellis W.   Russell K.   Lange P.H.  

Urology, Vol. 48, Iss. 5, 1996-11 ,pp. : 800-804

Elsevier

Access to resources Recommend Favorite

Patient-reported outcomes. How important are they?

By Korolija D.   Wood-Dauphinee S.   Pointner R.  

Surgical Endoscopy, Vol. 21, Iss. 4, 2007-04 ,pp. : 503-507

Springer Publishing Company

Access to resources Recommend Favorite